PMID- 28357111
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 6
IP  - 2
DP  - 2017 Feb
TI  - Typing of killer-cell immunoglobulin-like receptors and their cognate human 
      leukocyte antigen class I ligands predicts survival of Chinese Han patients with 
      metastatic non-small-cell lung cancer.
PG  - 279-285
LID - 10.3892/mco.2016.1106 [doi]
AB  - Non-small-cell lung cancer (NSCLC) may establish an immunosuppressive tumor 
      microenvironment that is conducive to tumor growth. Natural killer (NK) cells 
      play a pivotal role in immunological surveillance. Activation of NK cells 
      partially depends on the interactions between killer-cell immunoglobulin-like 
      receptors (KIRs) and human leukocyte antigen (HLA) class I ligands. We herein 
      investigated the association of KIRs and HLA ligands with survival in metastatic 
      NSCLC (mNSCLC) patients treated with chemotherapy in a Chinese Han population. 
      Polymerase chain reaction with sequence-specific primers was used to type 15 KIRs 
      at the DNA and mRNA level and 6 HLA ligands in 70 mNSCLC patients. Survival 
      curves were estimated using the Kaplan-Meier method and compared with the 
      log-rank test. Cox proportional hazard regression model was applied for 
      multivariate survival analysis, with the stepwise selection, to determine 
      independent predictors of survival. It was observed that patients with KIR2DS4del 
      gene expression at the mRNA level or HLA-Bw4T80 exhibited poor overall survival 
      (OS). The multivariate analysis revealed that HLA-Bw4T80 and KIR2DS4del 
      expression were independent predictors of OS. This observation indicated that the 
      KIR/HLA ligand is a promising predictor of survival in mNSCLC and may also 
      provide a strategy for treatment stratification and patient management.
FAU - Yu, Hui
AU  - Yu H
AD  - Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 
      200032, P.R. China; Department of Oncology, Shanghai Medical College, Fudan 
      University, Shanghai 200032, P.R. China.
FAU - Liu, Fang
AU  - Liu F
AD  - Fudan University Shanghai Cancer Center-Institut Merieux Laboratory, Shanghai 
      200032, P.R. China; Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd., 
      Shanghai 201315, P.R. China.
FAU - Sansas, Benoit
AU  - Sansas B
AD  - Transgene S.A., 67405 Illkirch Graffenstaden, France.
FAU - Kang, Bin
AU  - Kang B
AD  - Fudan University Shanghai Cancer Center-Institut Merieux Laboratory, Shanghai 
      200032, P.R. China.
FAU - Preville, Xavier
AU  - Preville X
AD  - Transgene S.A., 67405 Illkirch Graffenstaden, France.
FAU - Wu, Xianghua
AU  - Wu X
AD  - Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 
      200032, P.R. China; Department of Oncology, Shanghai Medical College, Fudan 
      University, Shanghai 200032, P.R. China.
FAU - Chang, Jianhua
AU  - Chang J
AD  - Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 
      200032, P.R. China; Department of Oncology, Shanghai Medical College, Fudan 
      University, Shanghai 200032, P.R. China.
FAU - Micol, Romain
AU  - Micol R
AD  - Transgene S.A., 67405 Illkirch Graffenstaden, France.
FAU - Wang, Jialei
AU  - Wang J
AD  - Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 
      200032, P.R. China; Department of Oncology, Shanghai Medical College, Fudan 
      University, Shanghai 200032, P.R. China.
FAU - Meng, Xia
AU  - Meng X
AD  - Fudan University Shanghai Cancer Center-Institut Merieux Laboratory, Shanghai 
      200032, P.R. China; Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd., 
      Shanghai 201315, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20161212
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC5351717
OTO - NOTNLM
OT  - human leukocyte antigen
OT  - killer-cell immunoglobulin-like receptor
OT  - non-small-cell lung cancer
OT  - prognosis
EDAT- 2017/03/31 06:00
MHDA- 2017/03/31 06:01
PMCR- 2016/12/12
CRDT- 2017/03/31 06:00
PHST- 2016/07/14 00:00 [received]
PHST- 2016/11/09 00:00 [accepted]
PHST- 2017/03/31 06:00 [entrez]
PHST- 2017/03/31 06:00 [pubmed]
PHST- 2017/03/31 06:01 [medline]
PHST- 2016/12/12 00:00 [pmc-release]
AID - MCO-0-0-1106 [pii]
AID - 10.3892/mco.2016.1106 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2017 Feb;6(2):279-285. doi: 10.3892/mco.2016.1106. Epub 2016 Dec 
      12.